Browsing: Biotech

The biotech sector’s performance over the past 18 months has “more than made up for a challenging 2+ year period,” analysts from Truist Securities said. And with regulatory risks abating, M&A already topping 2025 and more positive trends underway, the firm believes the momentum will continue through the end of the year.

ProtoKinetix, Inc. (PKTX) filed its annual report as a development-stage biotechnology company focused on anti-freeze glycoproteins (AAGP®) for cell, tissue and organ preservation and other medical uses.

A new report found that the sizes of seed rounds and Series A financings for Massachusetts biotech startups are going in opposite directions.

New government funding from Pennsylvania to Kansas City is strengthening biotech hubs — but experts say money alone won’t determine where pharma builds next.

VanEck Pharmaceutical ETF (NASDAQ:PPH) provides lower-cost exposure to established drug manufacturers with lower historical volatility, while Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) targets high-growth biotech companies at a higher expense.

Ying Huang is now running K2 Therapeutics, which has licensed multiple prospects from China-based biotechs and is searching for more “high-potential” medicines.

Hamburg-based AquaNab has secured investment to advance its nanoantibody platform, initially targeting sea lice in salmon farming and developing feed-administered treatments for aquaculture diseases. Tamara Djurickovic4 minutes ago

HONG KONG, Aug. 10, 2026 /PRNewswire/ — Per BIOHK2025 official briefing materials, a Swiss cell therapy biotech founder scans the bustling conference floor of BIOHK2025, shaking hands with Nobel laureates, Hong Kong financial regulators, mainland biotech lab directors and Asia-focused venture capitalists all within a single day. For decades, his firm chased dual goals: breaking…

UK biotech companies raised £2.05 billion ($2.76 billion) in venture capital in the second quarter of 2026, the strongest quarter for the sector in five years, according to new figures from theBioIndustry Association (BIA).

Poor visualization techniques can oversimplify reality and make data less potent.